Form 4: Dermata Therapeutics SVP, CFO Van Hoose Acquires Shares and Warrants in Private Placement

Kyri K. Van Hoose, SVP and CFO of Dermata Therapeutics, acquired 78,741 shares of common stock and accompanying warrants in a private placement on January 21, 2025.

Summary

• On January 21, 2025, Kyri K. Van Hoose, the SVP and CFO of Dermata Therapeutics, acquired 78,741 shares of common stock and accompanying warrants.
• The transaction occurred through a private placement at a price of $1.27 per share and warrant.
• The warrants are exercisable upon stockholder approval of the issuance of shares related to the warrants issued in the private placement and will expire five years from the effective date of stockholder approval.
• The warrant exercise is limited such that Van Hoose, together with affiliates, cannot beneficially own more than 9.99% of the outstanding common stock after the exercise, subject to certain exceptions.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine filing. Insider buying can be seen as a positive signal, but it's a relatively small amount.

Positives

• The purchase by a key executive could signal confidence in the company's prospects.

Risks

• The warrant exercise is contingent on stockholder approval, which is not guaranteed.
• The 9.99% ownership cap on warrant exercise could limit potential gains.

Future Outlook

The warrants will become exercisable upon stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval.

Industry Context

Private placements are a common method for companies, especially smaller ones like Dermata Therapeutics, to raise capital. Insider participation can be viewed positively by the market.

Comparison to Industry Standards

• Similar private placements in the biotech industry often involve warrants to incentivize investment.
• The warrant exercise cap of 9.99% is a common provision to avoid triggering change-of-control provisions or other regulatory thresholds.
• The $1.27 purchase price needs to be evaluated against the prevailing market price of DRMA shares to determine if it represents a premium or discount.

Related Party Transactions

• The purchase of shares and warrants by the SVP, CFO constitutes a related party transaction.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment if viewed as a sign of confidence by a key executive.

Next Steps

• Dermata Therapeutics will need to seek stockholder approval for the issuance of shares related to the warrants.

Key Dates

Keywords

private placement, warrants, common stock, Dermata Therapeutics, Van Hoose, DRMA, SVP, CFO, acquisition